Literature DB >> 10889910

Proteolysis in human breast cancer.

E A Garbett1, M W Reed, T J Stephenson, N J Brown.   

Abstract

BACKGROUND: The process of proteolysis is important at several stages of the metastatic cascade. A balance between the expression of the genes encoding endogenous proteinases and inhibitors exists and when the production of proteinases exceeds that of inhibitors proteolysis occurs. AIMS: To determine whether differences in the profile and activity of proteinases and inhibitors exist within breast tumour tissue (n = 51), surrounding background breast tissue (n = 43), normal breast tissue from breast reduction mammoplasty operations (n = 10), and cells of the breast cancer cell line, MCF-7.
METHODS: Proteinase (matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, MMP-9, urokinase-type plasminogen activator (uPA), and tissue-type PA (tPA)) and inhibitor (tissue inhibitor of metalloproteinases; TIMP-1 and TIMP-2) expression and proteinase activity were compared using substrate zymography, western blotting, immunohistochemistry, and quenched fluorescent substrate hydrolysis.
RESULTS: The presence of all proteinases and inhibitors was greater in breast tumour tissue when compared with all other types of breast tissue (p < 0.05). The activity of total MMPs as determined by quenched fluorescent substrate hydrolysis was also greater in breast tumours (p < 0.05).
CONCLUSIONS: There is increased proteolysis in human breast tumours when compared with other breast tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889910      PMCID: PMC1186913          DOI: 10.1136/mp.53.2.99

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  28 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

Review 2.  Metalloproteinase inhibitors and the prevention of connective tissue breakdown.

Authors:  T E Cawston
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

3.  Classification of peptidases.

Authors:  A J Barrett
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

4.  Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology.

Authors:  M Polette; C Clavel; M Cockett; S Girod de Bentzmann; G Murphy; P Birembaut
Journal:  Invasion Metastasis       Date:  1993

5.  Expression of activated gelatinase in human invasive breast carcinoma.

Authors:  P D Brown; R E Bloxidge; E Anderson; A Howell
Journal:  Clin Exp Metastasis       Date:  1993-03       Impact factor: 5.150

6.  A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases.

Authors:  C G Knight; F Willenbrock; G Murphy
Journal:  FEBS Lett       Date:  1992-01-27       Impact factor: 4.124

7.  Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology.

Authors:  C Clavel; M Polette; M Doco; I Binninger; P Birembaut
Journal:  Bull Cancer       Date:  1992       Impact factor: 1.276

Review 8.  [The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis].

Authors:  H Iwata; S Kobayashi; H Iwase; Y Okada
Journal:  Nihon Rinsho       Date:  1995-07

9.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.

Authors:  A G Remacle; A Noël; C Duggan; E McDermott; N O'Higgins; J M Foidart; M J Duffy
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

10.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Authors:  C Bouchet; F Spyratos; P M Martin; K Hacène; A Gentile; J Oglobine
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more
  17 in total

1.  Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element.

Authors:  Karl E Miletti-González; Kyle Murphy; Muthu N Kumaran; Abhilash K Ravindranath; Roman P Wernyj; Swayamjot Kaur; Gregory D Miles; Elaine Lim; Rigel Chan; Marina Chekmareva; Debra S Heller; David Foran; Wenjin Chen; Michael Reiss; Elisa V Bandera; Kathleen Scotto; Lorna Rodríguez-Rodríguez
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

2.  Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis.

Authors:  Cory M Yamashita; Lior Dolgonos; Rachel L Zemans; Scott K Young; Jennifer Robertson; Natalie Briones; Tomoko Suzuki; Megan N Campbell; Jack Gauldie; Derek C Radisky; David W H Riches; Guoying Yu; Naftali Kaminski; Christopher A G McCulloch; Gregory P Downey
Journal:  Am J Pathol       Date:  2011-08-24       Impact factor: 4.307

3.  Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells.

Authors:  Luis Castro-Sanchez; Adriana Soto-Guzman; Margarita Guaderrama-Diaz; Pedro Cortes-Reynosa; Eduardo Perez Salazar
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

4.  Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth.

Authors:  Annette Lebeau; Claudia Müller-Aufdemkamp; Clarissa Allmacher; Ulrich Sauer; Andreas Nerlich; Ralf Lichtinghagen; Udo Löhrs
Journal:  J Mol Histol       Date:  2004-06       Impact factor: 2.611

5.  Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility.

Authors:  Alicia Beeghly-Fadiel; Wei Lu; Ji-Rong Long; Xiao-ou Shu; Ying Zheng; Qiuyin Cai; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

6.  PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.

Authors:  Laetitia Devy; Shafaat A Rabbani; Mark Stochl; Mary Ruskowski; Ian Mackie; Laurent Naa; Mark Toews; Reinoud van Gool; Jie Chen; Art Ley; Robert C Ladner; Daniel T Dransfield; Paula Henderikx
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

7.  Expression of proteinases and inhibitors in human breast cancer progression and survival.

Authors:  E A Baker; T J Stephenson; M W R Reed; N J Brown
Journal:  Mol Pathol       Date:  2002-10

8.  A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.

Authors:  Sangmin Kim; Jeonghun Han; Incheol Shin; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam
Journal:  Exp Mol Med       Date:  2012-08-31       Impact factor: 8.718

9.  Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature.

Authors:  Andrea Köhrmann; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Jelena Anacker
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

10.  Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma.

Authors:  A Talvensaari-Mattila; P Pääkkö; T Turpeenniemi-Hujanen
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.